Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad5-gag Therapeutic Vaccine in HIV
NCT02762045Phase 1Unknown
- Sponsor
- Centers for Disease Control and Prevention
- Start
- Apr 2016
- Primary completion
- Dec 2016
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MRKAd5 HIV-1 gag vaccine in human immunodeficiency virus infection (HIV) (3 arms), sponsored by Centers for Disease Control and Prevention. Primary endpoint: Occurrence, intensity and relationship to vaccination of local and systemic adverse events at 12 months. Status: unknown.
02
Drugs
MRKAd5 HIV-1 gag vaccine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02762045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02762045.